FHD-909

Ascentage Pharma's olverembatinib has received Breakthrough Therapy Designation from China's NMPA for first-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy.

Datopotamab deruxtecan (Dato-DXd) is poised to become a standard treatment for metastatic hormone receptor-positive, HER2-negative breast cancer after prior systemic therapy.

Foghorn Therapeutics' FHD-909, a SMARCA2 inhibitor, is progressing in Phase 1 trials for SMARCA4-mutated cancers, with NSCLC as the primary target, and combination data with pembrolizumab and KRAS inhibitors will be presented at AACR.

Foghorn Therapeutics halts independent development of FHD-286 with decitabine for relapsed/refractory AML due to insufficient response rates in Phase 1 trial.

Oncolytics Biotech's BRACELET-1 trial showed pelareorep, combined with paclitaxel, significantly improved survival rates in HR+/HER2- advanced or metastatic breast cancer patients.